- Longevity Research
- |
- Neuro Research
SLU-PP-332 5mg
Free Shipping on Orders Over $150!
Original price was: $80.00.$60.00Current price is: $60.00.
In stock
Chemical Information:
- Molecular Formula: C₁₈H₁₄N₂O₂
- Molecular Weight: 290.32 g/mol
- Chemical Name: (E)-4-Hydroxy-N’-(naphthalen-2-ylmethylene)benzohydrazide
- CAS Number: 303760-60-3
- Molecular Structure: Refer to Certificate of Analysis for detailed structural information.
Description:
SLU-PP-332 is a novel synthetic small molecule extensively studied for its role as an estrogen-related receptor (ERR) pan-agonist, primarily targeting ERRα, ERRβ, and ERRγ. Research indicates its potential in modulating metabolic pathways, enhancing mitochondrial function, and promoting energy expenditure. Provided in tablet or capsule preparation specifically for advanced laboratory research in metabolism, energy regulation, and cellular bioenergetics.
Storage and Handling:
-
Store sealed at recommended laboratory freezer temperatures.
-
Protect from light, moisture, and excessive heat.
-
Handle using standard laboratory safety procedures to maintain product integrity.
Product Specifications:
-
Purity: ≥99% (HPLC Verified)
-
Appearance: White to off-white lyophilized powder
-
Solubility: Refer to Certificate of Analysis for physicochemical properties
Important Note:
This product is strictly FOR RESEARCH USE ONLY and is intended exclusively for in vitro research and laboratory experimentation by qualified professionals. It is not a drug, food, cosmetic, or dietary supplement, and has not been evaluated by the FDA. This compound is not intended to diagnose, treat, cure, or prevent any disease. The bodily introduction into humans or animals is strictly prohibited by law. Any misuse, misbranding, or mislabeling is a violation of federal regulations and may result in legal action under applicable federal, state, or local laws.
References:
Referenced scientific publications include:
- Kim, D. K., & Ryu, D. (2022). “Targeting ERRs in Metabolic Disorders: Opportunities and Challenges.” Trends in Pharmacological Sciences.
- Wang, Y., & Burris, T.P. (2022). “Nuclear receptor-based drug development for metabolic diseases.” Journal of Medicinal Chemistry.
- Gatto, G. J., et al. (2020). “Selective Activation of Estrogen-Related Receptor Alpha (ERRα).” Cell Chemical Biology.








